⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7519557 | 0.69 | NISCH (0.31) | — | |
| SCHEMBL28575960 | 0.64 | — | — | |
| SCHEMBL6990535 | 0.60 | — | — | |
| SCHEMBL2497267 | 0.57 | — | — | |
| SCHEMBL419917 | 0.57 | CCR2 (0.31) | — | |
| SCHEMBL30041643 | 0.55 | — | — | |
| SCHEMBL30295004 | 0.55 | — | — | |
| SCHEMBL29187917 | 0.55 | HRH4 (0.32) | — | |
| SCHEMBL28950561 | 0.55 | HRH4 (0.32) | — | |
| SCHEMBL10731655 | 0.54 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098007-A1 | Compounds and Their Use in Filtering Ultraviolet and/or High-Energy Visible Light | SOLIOME INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20250388592-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2025-12-25 | — | — | US | disclosed |
| EP-4626860-A1 | FUSED PYRROLYL-SULFONAMIDE COMPOUNDS | ReWind Therapeutics NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4587007-A2 | COMPOUNDS AND THEIR USE IN FILTERING ULTRAVIOLET AND/OR HIGH-ENERGY VISIBLE LIGHT | Soliome, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4568968-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Remynd N.V. (BE) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025104081-A1 | TRIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025104092-A1 | MODULATORS OF SEPTIN 6 FOR USE IN THE PREVENTION AND/OR TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2025-05-22 | — | — | WO | disclosed |
| CN-120019060-A | Compounds and their use for filtering ultraviolet and/or high-energy visible light | 索利奥美公司 | 2025-05-16 | — | — | CN | disclosed |
| EP-3848035-B1 | 1,4-DISUBSTITUTED PYRIDAZINE COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-113717154-B | Methods for treating huntington's disease | PTC医疗公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024115733-A1 | FUSED PYRROLYL-SULFONAMIDE COMPOUNDS | REWIND THERAPEUTICS NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| EP-4347558-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | ReWind Therapeutics NV (BE) | 2024-04-10 | — | — | EP | disclosed |
| CN-117794898-A | 3-pyrrolylsulfonamide compounds as GPR17 antagonists | 瑞文德医疗公众有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2024059119-A2 | COMPOUNDS AND THEIR USE IN FILTERING ULTRAVIOLET AND/OR HIGH-ENERGY VISIBLE LIGHT | SOLIOME, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-3386511-B2 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2024033479-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2024-02-15 | — | — | WO | disclosed |
| US-20230201200-A1 | Methods for Treating Huntington’s Disease | PTC THERAPEUTICS INC (US) | 2023-06-29 | — | — | US | disclosed |
| US-11638706-B2 | Methods for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-11608501-B2 | Methods for modifying RNA splicing | PTC THERAPEUTICS, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| WO-2022254027-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | REWIND THERAPEUTICS NV (BE) | 2022-12-08 | — | — | WO | disclosed |